Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705193 | 1.00 | KMT2A (0.55) | KMT2AMAPTKDM4EKAT2BALDH1A1 | |
| SCHEMBL28845231 | 1.00 | KMT2A (0.55) | KMT2AMAPTKDM4EKAT2BALDH1A1 | |
| SCHEMBL14953718 | 0.87 | KAT2B (0.57) | KMT2AMAPTKDM4EKAT2BALDH1A1 | |
| SCHEMBL21973136 | 0.87 | MAPT (0.57) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL20402081 | 0.87 | MAPT (0.60) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL20415311 | 0.87 | KMT2A (0.55) | KMT2AMAPTKDM4EKAT2BALDH1A1 | |
| SCHEMBL3791900 | 0.86 | MAPT (0.47) | KMT2AMAPTKDM4EKAT2BALDH1A1 | |
| SCHEMBL20420152 | 0.86 | KAT2B (0.49) | KMT2AMAPTKAT2BALDH1A1POLB | |
| SCHEMBL20419961 | 0.86 | ALDH1A1 (0.57) | KMT2AMAPTKAT2BALDH1A1POLB | |
| SCHEMBL20420223 | 0.86 | KAT2B (0.70) | KMT2AMAPTKDM4EKAT2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| US-20190209572-A1 | BIFUNCTIONAL ANTIFUNGAL AGENTS AND METHODS OF TREATING FUNGAL INFECTION | MERCK SHARP & DOHME CORP. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209572-A1 | BIFUNCTIONAL ANTIFUNGAL AGENTS AND METHODS OF TREATING FUNGAL INFECTION | ERG28, PAICS, BAK1 | KMT2A 1118/4885MAPT 1751/4885KDM4E 1924/4885 |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | KMT2A 3572/4885MAPT 3689/4885KDM4E 4738/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | KMT2A 3699/4885MAPT 3357/4885KDM4E 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.